ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol-Myers Squibb CEO insists proposed Celgene purchase not a "defensive deal"
March 13, 2019Bristol-Myers Squibb CEO Giovanni Caforio reiterated that the company's proposed $74-billion acquisition of Celgene is not designed to fend-off a takeover of the company. This "is not [a] defensive deal," Caforio said, as the drugmaker looks to persuade i
Pharma Sources Insight January 2025
